Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced GIST While Safety More Favourable for Ripretinib By Ogkologos - June 2, 2025 68 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival and updated safety analysis of the INTRIGUE study Source RELATED ARTICLESMORE FROM AUTHOR Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer MOST POPULAR When He Said His Mother-In-Law Was Going To Live In The... March 6, 2019 Cancer-Free Bell Broken by Excited Patient Who Just Got Done Battling... July 17, 2019 Suzanne Somers Discusses Her Cancer Diagnosis And Thinking Of Her ‘Mortality’ January 6, 2020 How Sharing My Story Helps Me Cope With an Advanced Brain... April 15, 2021 Load more HOT NEWS Pine Trees or COVID? Kid Friendly Meals When Cancer Isn’t Your Only Challenge: How I Learned to Cope ESMO Announces Results of 2025 Elections
